Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL
Background: Nivolumab, an anti–programmed cell death 1 immuno-oncology therapy, is approved as an adjuvant treatment for patients with completely resected stage III or stage IV melanoma. PRESERV MEL (Prospective and REtrospective Study of nivolumab thERapy in adjuVant MELanoma) is a real-world observational study evaluating the effectiveness and safety of adjuvant nivolumab in patients with completely resected stage III or stage IV melanoma in clinical practice in Belgium and Luxembourg. Methods: Patients were enrolled prospectively and retrospectively during a 2-year period (January 2019–Janu... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Reihe/Periodikum: | Cancers, Vol 15, Iss 4823, p 4823 (2023) |
Verlag/Hrsg.: |
MDPI AG
|
Schlagwörter: | adjuvant treatment / effectiveness / health-related quality of life / melanoma / nivolumab / real-world / Neoplasms. Tumors. Oncology. Including cancer and carcinogens / RC254-282 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27517599 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.3390/cancers15194823 |